Linked Data API

Show Search Form

Search Results

1123746
star this property registered interest false more like this
star this property date less than 2019-04-29more like thismore than 2019-04-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Antibiotics: Drug Resistance more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the effectiveness of their 2013–18 antimicrobial resistance strategy at addressing the problem of multi-resistant E. coli-like bacteria; what assessment they have made of recent trends in the number of multi-resistant E. coli-like bacteria in the UK; and what factors inform their view of the balance between efforts to reduce transmission and efforts to reduce the use of antibiotics. more like this
star this property tabling member printed
Baroness Gardner of Parkes more like this
star this property uin HL15384 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>While we can count many successes from our 2013-18 Antimicrobial Resistance (AMR) Strategy, resistance has continued to increase. In the United Kingdom we have seen a 35% increase in resistant blood stream infections in humans from 2013-17.</p><p>The number of bloodstream infections (BSIs) is increasing each year. Although the proportion of antibiotic resistant BSIs remain stable year to year, the burden on resistance increases. This is mostly due to increasing prevalence of E.coli bloodstream infections.</p><p>Estimates of the multi-resistant cases can be made, however not all the bacteria are tested against the same antibiotics, so a definitive number of cases cannot be given. The Public Health England Fingertips tool also has an indicator showing the rolling quarterly average proportion of E. coli blood specimens non-susceptible to at least three of the key antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cephalosporins or carbapenems). For England this is 5.5% with little fluctuation over time.</p><p>This is exactly why the UK’s five-year national action plan for AMR, published alongside the UK 20-year vision for AMR on 24 January 2019, includes a strengthened focus on infection prevention and control, renewing our commitment to halve levels of healthcare associated Gram-negative blood stream infections (mostly E.coli) by 2023-24. The plan also sets a world-first target to reduce the actual numbers of resistant infections, with the aim to reduce them by 10% by 2025.</p><p>We are working with the devolved health administrations to develop consistent methodologies for reporting the incidence and mortality of key antibiotic resistant infections and antimicrobial use to allow us to report progress on the ambitions of the AMR national action plan.</p><p>As reductions in inappropriate prescribing also reduces the risk of promoting the growth of antibiotic-resistant bacteria, interventions to reduce antibiotic prescribing or transmission of the bacteria are complementary.</p><p> </p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-05-14T16:29:42.253Zmore like thismore than 2019-05-14T16:29:42.253Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3596
star this property label Biography information for Baroness Gardner of Parkes more like this
1124588
star this property registered interest false more like this
star this property date less than 2019-05-02more like thismore than 2019-05-02
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Prescriptions: Fees and Charges more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 April 2019 to Question 245660 on Prescriptions: Fees and Charges, what the annual cost is to the NHS Business Services Authority's Loss Recovery Service of (a) checking prescription form exemption declarations, (b) issuing Penalty Charge Notices and (c) managing associated customer contact. more like this
star this property tabling member constituency Knowsley more like this
star this property tabling member printed
Mr George Howarth more like this
star this property uin 250443 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>In 2018-19 the cost to the NHS Business Services Authority for the running of the Prescription Exemption Checking Service which includes, checking prescription form exemption declarations, issuing Penalty Charge Notices and managing associated customer contact was £8.41 million.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-14T15:26:42.82Zmore like thismore than 2019-05-14T15:26:42.82Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
481
star this property label Biography information for Sir George Howarth more like this
1124682
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Speech Therapy: Children more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether Public Health England has plans to issue guidance to (a) parents and (b) carers on (i) identifying need for and (ii) access to speech, language and communication services for children . more like this
star this property tabling member constituency Swansea West more like this
star this property tabling member printed
Geraint Davies more like this
star this property uin 250735 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>Public Health England (PHE) is working in partnership with the Department for Education to produce evidence-based resources and tools to support health visitors, early years practitioners and parents/carers in identifying and supporting children’s early speech, language and communication (SLC) needs through training guidance and an enhanced early language assessment tool. The assessment tool will incorporate parent resources to support family understanding of SLC in their children and will be rolled out from April 2020.</p><p> </p><p>Alongside this work, PHE is developing a model SLC pathway for children under five. This will ensure that professionals working with families are able to help them support their child’s SLC and how to access support if needed. The pathway will be published by September 2019.</p> more like this
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-05-14T16:09:38.827Zmore like thismore than 2019-05-14T16:09:38.827Z
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
155
star this property label Biography information for Geraint Davies more like this
1124720
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Idiopathic Pulmonary Fibrosis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) early diagnosis and (b) treatment of idiopathic pulmonary fibrosis. more like this
star this property tabling member constituency Stevenage more like this
star this property tabling member printed
Stephen McPartland more like this
star this property uin 250788 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>The United Kingdom Rare Disease Strategy, published in 2013, sets out our commitment to raising awareness about all rare diseases including idiopathic pulmonary fibrosis (IPF) and our strategic vision for improving the lives of all those affected. The Strategy promotes improvements to ensure that people living with a rare disease receive high-quality care.</p><p>The Government recognizes the need for awareness raising and training of health care professionals for rare diseases. This is being taken forward through the work of the UK Rare Diseases Policy Board and NHS England’s Rare Diseases Implementation plan, which commits NHS England to engaging with the Royal College of General Practitioners (GPs) and the Nursing and Midwifery Council on opportunities for GPs and health visitors to recognise and facilitate earlier diagnosis of rare diseases.</p><p>There are limited drug treatment options for IPF and two drugs, Pirfenidone and Nintedanib, are commissioned following National Institute for Health and Care Excellence Technology Appraisals. Alongside this, the Department funds research into rare diseases such as IPF through the National Institute for Health Research (NIHR).</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:35:47.667Zmore like thismore than 2019-05-15T16:35:47.667Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4093
star this property label Biography information for Stephen McPartland more like this
1124729
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Speech Therapy: Children and Young People more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS Clinical Commissioners on the importance of joint commissioning services for children and young people with speech, language and communication needs. more like this
star this property tabling member constituency Swansea West more like this
star this property tabling member printed
Geraint Davies more like this
star this property uin 250739 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>The Department has had no discussions with the organisation NHS Clinical Commissioners on joint commissioning of services for children and young people with speech, language and communication needs.</p> more like this
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-05-14T16:06:09.57Zmore like thismore than 2019-05-14T16:06:09.57Z
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
155
star this property label Biography information for Geraint Davies more like this
1124901
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Nusinersen more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what discussions they have had with (1) NICE, (2) NHS England, and (3) Biogen, on a Managed Access Agreement for Spinal Muscular Atrophy treatment, Spinraza. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15576 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15577 more like this
star this property question first answered
less than 2019-05-17T11:07:46.62Zmore like thismore than 2019-05-17T11:07:46.62Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
star this property label Biography information for Baroness Thomas of Winchester more like this
1124902
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15577 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15576 more like this
star this property question first answered
less than 2019-05-17T11:07:46.673Zmore like thismore than 2019-05-17T11:07:46.673Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
star this property label Biography information for Baroness Thomas of Winchester more like this
1124918
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that haemophilia patients receive (a) appropriate access to physiotherapy, (b) a regular clinical review, and (c) tailored dosing of treatments in accordance with NHS England’s service specification. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251321 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251322 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.547Zmore like thismore than 2019-05-15T16:14:44.547Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124919
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Commercial Medicines Unit’s national tender framework for factor VIII haemophilia products on patient access to extended half-life medicines. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251322 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.61Zmore like thismore than 2019-05-15T16:14:44.61Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124920
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Blood Diseases: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he NHS England is taking to ensure that patients with bleeding disorders have adequate access to treatment options that meet individual patient need. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251323 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251322 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.657Zmore like thismore than 2019-05-15T16:14:44.657Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this